Improving the immunogenicity of DNA vaccines: A nano-sized task?
Taki, Aya C., Kikidopoulos, Natalie, Baird, Fiona J., and Smooker, Peter M. (2011) Improving the immunogenicity of DNA vaccines: A nano-sized task? In: Donnelly, Erin C., and Dixon, Arthur M., (eds.) DNA Vaccines: types, advantages and limitations. Immunology and Immune System Disorders . Nova Science Publishers, Inc., New York, NY, USA, pp. 37-66.
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
A major biotechnological revolution of the last two decades has resulted in the novel application of DNA as a vaccine to prevent or treat disease. This has progressed from principle to product in only 20 years. However, the wider application of DNA vaccines is reliant on improving their immunogenicity, as while DNA vaccination can provide a broad immune response to an antigen, the magnitude is often less than optimal. This has led to many studies into improving the immunogenicity by using different delivery methods, targeting to specific cells in the host and by co-delivery with potent immune stimulators. Here we will review the different methodologies used to improve the immunogenicity of DNA vaccines, designed to maximise immunogenicity without changing the fundamental simplicity and usability of this type of vaccine. The most recent innovations, of delivery using nanoparticles, are also highlighted.
Item ID: | 44270 |
---|---|
Item Type: | Book Chapter (Research - B1) |
ISBN: | 978-161324444-9 |
Keywords: | DNA vaccine; immunogenicity; nanoparticle |
Date Deposited: | 07 Jun 2016 02:24 |
FoR Codes: | 10 TECHNOLOGY > 1007 Nanotechnology > 100709 Nanomedicine @ 50% 11 MEDICAL AND HEALTH SCIENCES > 1107 Immunology > 110799 Immunology not elsewhere classified @ 20% 10 TECHNOLOGY > 1004 Medical Biotechnology > 100499 Medical Biotechnology not elsewhere classified @ 30% |
SEO Codes: | 86 MANUFACTURING > 8608 Human Pharmaceutical Products > 860801 Human Biological Preventatives (e.g. Vaccines) @ 100% |
Downloads: |
Total: 3 |
More Statistics |